Syncom Formulations (India) Limited (NSE:SYNCOMF)
11.30
+0.13 (1.16%)
Apr 2, 2026, 3:29 PM IST
NSE:SYNCOMF Revenue
Syncom Formulations (India) had revenue of 1.15B INR in the quarter ending December 31, 2025, a decrease of -9.72%. This brings the company's revenue in the last twelve months to 5.03B, up 28.65% year-over-year. In the fiscal year ending March 31, 2025, Syncom Formulations (India) had annual revenue of 4.65B with 76.55% growth.
Revenue (ttm)
5.03B
Revenue Growth
+28.65%
P/S Ratio
2.11
Revenue / Employee
6.76M
Employees
744
Market Cap
10.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.65B | 2.02B | 76.55% |
| Mar 31, 2024 | 2.63B | 391.33M | 17.45% |
| Mar 31, 2023 | 2.24B | 45.91M | 2.09% |
| Mar 31, 2022 | 2.20B | -251.42M | -10.27% |
| Mar 31, 2021 | 2.45B | 392.94M | 19.12% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.60B |
| Solara Active Pharma Sciences | 12.55B |
| Windlas Biotech | 8.68B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 6.74B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.85B |